Abstract:
We have established the efficacy of proteolysis inhibitor (PI) aminocaproic acid (ACA) in viral infections as a result of its impact on the etiological factor and pathogenesis of the infection. The Ministry of Health of Ukraine on the basis of our studies and clinical trials allowed using ACA for prophylaxis and treatment of influenza and other acute respiratory viral infections (ARVI). Including ACA to therapeutic complex for the treatment of influenza and other ARVI in children and neonates led to a decrease of the duration of symptoms of intoxication, catarrhal phenomena, and fever as well as to a decrease of the number of complications. The prevention effectiveness of ACA has also been established. The obtained results allow to recommend the use of ACA for the efficient prophylaxis of ARVIs and pneumonia in organized collectives in the period of increased incidences of these infections. Our research has shown that the combined use of drugs with different mechanisms of action - PI ACA and neuraminidase inhibitor Tamiflu - causes a synergistic effect. We also studied the antibacterial action of ACA on S. aureus strains with different sensitivity to antibiotics. ACA inhibits all these strains, and the combined use of ACA with antibiotics magnifies the antibacterial effect.
